CT1 12.5% 1.4¢ ccp technologies limited

exstracts from bioshares report on agx from friday

  1. ds
    7,132 Posts.
    "Thrombowview has taken centre stage and for good reason"
    "Agenix is one of the most outstanding longer term growth opportunities in this sector"
    "What leaves considerable upside with this stock is the company's approach to commercialisation."
    "Set to supersede other blood clot imaging techniques"
    "Thrombowview has the potential to make Agenix a very significant Australian healthcare company."
    "the significant progress in the Thrombowview project warrants Bioshares maintaining a STRONG BUY recommendation in this stock."

    www.bioshares.com.au

    I have absolutely nothing to do with bioshares but think we should all subscribe to support this type of research.

    I do have a crapload of AGX shares.
 
watchlist Created with Sketch. Add CT1 (ASX) to my watchlist
(20min delay)
Last
1.4¢
Change
-0.002(12.5%)
Mkt cap ! $13.96M
Open High Low Value Volume
1.6¢ 1.6¢ 1.2¢ $134.1K 10.28M

Buyers (Bids)

No. Vol. Price($)
1 650000 1.4¢
 

Sellers (Offers)

Price($) Vol. No.
1.5¢ 120000 1
View Market Depth
Last trade - 16.10pm 15/11/2019 (20 minute delay) ?
(live)
Last
1.4¢
  Change
-0.002 ( 17.7 %)
Open High Low Volume
1.7¢ 1.7¢ 1.2¢ 1111570
Last updated 15.14pm 15/11/2019 (live) ?
CT1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.